In this article, we discuss the 5 low float stocks with high volume. If you want to read about some more low float stocks with high volume, go directly to 12 Low Float Stocks With High Volume.
5. Jiuzi Holdings, Inc. (NASDAQ:JZXN)
Number of Hedge Fund Holders: 3
Shares Float: 10.61 million
Avg Volume for 10 days: 1.35 million
Jiuzi Holdings, Inc. (NASDAQ:JZXN) franchises and operates Jiuzi retail stores that sell new energy vehicles, plug-in electric vehicles, and related components and parts. On September 9, Jiuzi Holdings revealed that it had signed a purchase deal with a DFSK Motor subsidiary. As part of the deal, DFSK Motor will deliver 5,000 micro-electric passenger cars customized for Jiuzi subsidiary, Hangzhou Jiuyao New Energy Automobile Technology.
At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $76,000 in Jiuzi Holdings, Inc. (NASDAQ:JZXN, compared to 2 in the preceding quarter worth $73,000.
Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in Jiuzi Holdings, Inc. (NASDAQ:JZXN) with 157,684 shares worth more than $48,000.
4. iBio, Inc. (NYSE:IBIO)
Number of Hedge Fund Holders: 3
Shares Float: 8.9 million
Avg Volume for 10 days: 594,000
iBio, Inc. (NYSE:IBIO) is a biotechnology company that provides contract development and manufacturing services to collaborators and third-party customers in the United States. On December 7, the share price of the firm slid by more than 30% after it priced it’s previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock, Series A warrants to purchase up to 3,365,385 shares of common stock.
At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $666,000 in iBio, Inc. (NYSE:IBIO), compared to 4 in the previous quarter worth $1.7 million.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Millennium Management is a leading shareholder in iBio, Inc. (NYSE:IBIO) with 2.4 million shares worth more than $414,000.
3. Baudax Bio, Inc. (NASDAQ:BXRX)
Number of Hedge Fund Holders: 3
Shares Float: 0.5 million
Avg Volume for 10 days: 1.39 million
Baudax Bio, Inc. (NASDAQ:BXRX) is a pharmaceutical company that develops and commercializes products for hospitals and other acute care settings. On November 30, the share price of the firm jumped after its Board of Directors approved a 1-for-40 reverse stock split of its shares.
At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $173,000 in Baudax Bio, Inc. (NASDAQ:BXRX), compared to 4 the preceding quarter worth $703,000.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Sabby Capital is a leading shareholder in Baudax Bio, Inc. (NASDAQ:BXRX) with 439,220 shares worth more than $108,000.
2. BioVie Inc. (NASDAQ:BIVI)
Number of Hedge Fund Holders: 3
Shares Float: 7.04 million
Avg Volume for 10 days: 2.54 million
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. On December 6, BioVie Inc shares soared after it provided additional data from a Phase 2 trial for its Alzheimer’s candidate NE3107 to suggest its impact on biomarkers of aging-related diseases.
At the end of the third quarter of 2022, 3 hedge funds in the database of Insider Monkey held stakes worth $394,000 in BioVie Inc. (NASDAQ:BIVI), compared to 2 in the preceding quarter worth $933,000.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Sabby Capital is a leading shareholder in BioVie Inc. (NASDAQ:BIVI) with 98,048 shares worth more than $244,000.
1. Ambrx Biopharma Inc. (NYSE:AMAM)
Number of Hedge Fund Holders: 7
Shares Float: 5.25 million
Avg Volume for 10 days: 506,000
Ambrx Biopharma Inc. (NYSE:AMAM) is a clinical-stage biologics company that discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. On December 9, Ambrx Biopharma stock climbed more than 150% after reporting preliminary data from a phase 2 trial of ARX788 in patients with HER2+ metastatic breast cancer who were previously treated with Roche’s Kadcyla.
On October 19, investment advisory Baird maintained an Outperform rating on Ambrx Biopharma Inc. (NYSE:AMAM) stock and lowered the price target to $4 from $8. Analyst Joel Beatty issued the ratings update.
At the end of the third quarter of 2022, 7 hedge funds in the database of Insider Monkey held stakes worth $6.6 million in Ambrx Biopharma Inc. (NYSE:AMAM), compared to 7 the preceding quarter worth $16.6 million.
Among the hedge funds being tracked by Insider Monkey, Boston-based investment firm Cormorant Asset Management is a leading shareholder in Ambrx Biopharma Inc. (NYSE:AMAM) with 2.3 million shares worth more than $2.5 million.
You can also take a peek at 10 Best ASX Stocks To Buy and 15 Most Creative Companies in the World.
